Dr. Bendell on the Future of Regorafenib for Patients With CRC

Johanna C. Bendell, MD
Published: Wednesday, Nov 15, 2017



Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Further studies need to be done to determine the best dosage for regorafenib because most patients cannot tolerate the current dose, says Bendell.

A current trial conducted by researchers out of Mayo Clinic is comparing the full dosage to a lower dosage to see if tolerability will translate into increased progression-free survival, explains Bendell.


Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Further studies need to be done to determine the best dosage for regorafenib because most patients cannot tolerate the current dose, says Bendell.

A current trial conducted by researchers out of Mayo Clinic is comparing the full dosage to a lower dosage to see if tolerability will translate into increased progression-free survival, explains Bendell.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x